Geographic Atrophy: A Small Implant Slowed Lesion Growth by 54% in a 30-Patient Phase 2 Trial

Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration. Patches of retinal tissue at the center of vision slowly die and expand. Treatments that slow GA exist, but they require frequent injections and do not restore vision, so researchers are testing other approaches.

A different target: the inflammasome

At the American Academy of Ophthalmology 2026 meeting, Liangbo Shen, MD, a retina fellow at Duke University, presented phase 2 results for kamuvudine K8, from Inflammasome Therapeutics. He described the inflammasome as a “smoke detector” inside cells that senses stress from altered fats, oxidation, and immune activity. Blocking it aims to quiet several of the processes that drive dry AMD at once.

How the study was designed

The U.S. multicenter trial enrolled 30 people with GA in both eyes. The worse-seeing eye received one of three doses of K8 at the start and at month 3, and the untreated other eye served as the comparison. Because GA tends to grow at similar rates in a person’s two eyes, this design needs fewer participants.

What was reported

• At the 0.7-mg dose, GA growth was reduced by 54% over 6 months compared with the untreated eye (43% in the first 3 months and 70% in the next 3).
• In a prespecified group of eyes whose lesions did not involve the very center, vision was 4 letters better than in the comparison eyes, although the study was not designed to measure vision.
• No drug-related serious side effects occurred through 6 months, with no increase in wet AMD or eye inflammation.
• K8 is a dissolving implant placed in the office through a small needle; if approved, dosing would be every 3 months.

Keep it in perspective

This was a small, short study presented at a meeting. Dr. Shen said a larger phase 3 trial with longer follow-up is needed. K8 is investigational and not FDA approved.

If you have dry AMD

• Have regular retina exams and imaging so GA is detected and measured.
• Ask whether AREDS2-type vitamins are right for your stage of AMD.
• Do not smoke, and check each eye for new distortion.

GA is managed by retina specialists; ask your eye doctor about a referral. For more reading, see lalasikcost.com.

Source: AAO 2026: Kamuvudine K8 slows geographic atrophy growth in phase 2 (Ophthalmology Times, 10/11/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.